Guggenheim raised its price objective on NewAmsterdam Pharma Co NV (NASDAQ:NAMS) to $45 from $41 on Wednesday and reaffirmed a Buy rating, citing an accelerated timetable for the company’s cholesterol agent obicetrapib in the European Union. At the time of the note, NAMS shares were trading at $35.76, reflecting a market capitalization of $4.11 billion.
The research house specifically moved its EU launch expectation forward to 2027 from an earlier projection of 2029, and folded that timing into the new target. Guggenheim’s outlook sits alongside a broader analyst consensus that the stock is viewed positively by many on the Street; published price targets among analysts run from $37.58 to $59.75.
Despite the bullish positioning, third-party data from InvestingPro indicates the shares still trade above the platform’s Fair Value estimate, suggesting the stock may be currently overvalued relative to that proprietary benchmark.
Clinical and regulatory cadence
Company management has signaled confidence in the progress of PREVAIL, the Phase 3 cardiovascular outcomes trial for obicetrapib, and has guided to an investor update by mid-2026. Management’s timing is driven by continued adjudication of events through at least two years of follow-up. Guggenheim, for its part, anticipates topline PREVAIL data by early 2027.
Investors will have an intermediate data point before then: NewAmsterdam is due to report quarterly results on March 4, roughly 13 days from now, and that earnings release may include more detail on trial progress.
On the regulatory front, the marketing authorization application for obicetrapib and the combination obicetrapib plus ezetimibe, filed by commercial partner Menarini, is reported to be on track for broad approvals across EU jurisdictions and the United Kingdom beginning in the second half of 2026. Additionally, results from the Phase 3 RUBENS study in patients with elevated LDL-C and either Type 2 diabetes or metabolic syndrome are expected in 2026.
Competitive context and analyst reactions
Guggenheim noted that the outcome of Novartis and Ionis’ Lp(a) HORIZON cardiovascular trial, expected in the second half of 2026, could represent an important inflection for obicetrapib because of its lipid-lowering characteristics. The firm described that event as a potential untethering moment for obicetrapib, given how the competitive landscape may shift based on HORIZON’s results.
Separately, Leerink Partners raised its price target on NewAmsterdam to $55 from $45 and maintained an Outperform rating. Leerink characterized obicetrapib as a differentiated cardiovascular platform with late-stage programs that, in the firm’s view, are not fully recognized by the market.
Taken together, the analyst moves, regulatory filings, and trial timelines supply a roadmap of clinical and commercial catalysts for NewAmsterdam over the next 12 to 24 months.
Implications for investors
The revised Guggenheim target and other analyst adjustments underscore how regulatory timing and late-stage outcomes are key value drivers for NewAmsterdam. Market participants will likely monitor upcoming trial readouts, the March 4 earnings update, and regulatory decisions in the second half of 2026 for signals that could confirm or challenge current analyst assumptions.